サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1597295

内分泌検査の世界市場の評価：検査タイプ別、技術別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Endocrine Testing Market Assessment, By Test Type, By Technology, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 240 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
内分泌検査の世界市場の評価：検査タイプ別、技術別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年11月26日
発行: Market Xcel - Markets and Data
ページ情報: 英文 240 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の内分泌検査の市場規模は、2023年の130億3,000万米ドルから2031年に244億2,000万米ドルに達すると予測され、2024年～2031年の予測期間にCAGRで8.17%の成長が見込まれます。市場の成長を支えているのは、内分泌疾患の罹患率の上昇、予防医療に対する意識の高まり、市場参入企業による機能や患者の利便性を高めた製品の発売の増加です。2023年8月、米国食品医薬品局（FDA）はMira Fertility Ovum Wandを尿中の卵胞刺激ホルモン（FSH）レベルを追跡するOTCツールとしてリストアップしました。このワンドは、生殖能力の評価、更年期の予測、排卵予測のサポートに向け、研究室の正確なFSHレベルを提供することができます。

内分泌検査は、内分泌系の異常や不均衡を特定し、生殖問題、糖尿病、甲状腺障害などの健康状態を管理し早期発見するためのホルモンレベルの評価に不可欠です。これらの検査へのアクセスや入手性を強化するための医療部門による投資の増加は、市場の拡大にプラスの影響を与えると予測されます。

さらに、一般住民の内分泌疾患に対する意識の高まりや、内分泌検査へのアクセシビリティを高めるためのさまざまな医療機関による取り組みの増加は、市場に有利な成長機会をもたらしています。複数の医療機関や政府機関は、糖尿病や甲状腺疾患を発症するリスクが高い集団の定期検診にますます力を入れるようになっています。一方、一般住民は健康意識の高まりから、潜在的な健康問題を早期に発見するために定期的な健康診断を求めるようになっています。さらに、予防医療へのシフトも、世界中のさまざまな地域における内分泌検査の需要を促進しています。

当レポートでは、世界の内分泌検査市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の内分泌検査市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 検査タイプ別
    • 技術別
    • エンドユーザー別
    • 地域別
    • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
  • 市場マップ分析（2023年）
    • 検査タイプ別
    • 技術別
    • エンドユーザー別
    • 地域別

第5章 北米の内分泌検査市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 検査タイプ別
    • 技術別
    • エンドユーザー別
    • シェア：国別
  • 各国の市場の評価
    • 米国の内分泌検査市場の見通し（2017年～2031年）
    • カナダ
    • メキシコ

第6章 欧州の内分泌検査市場の見通し（2017年～2031年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • ポーランド

第7章 アジア太平洋の内分泌検査市場の見通し（2017年～2031年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米の内分泌検査市場の見通し（2017年～2031年）

  • ブラジル
  • アルゼンチン

第9章 中東・アフリカの内分泌検査市場の見通し（2017年～2031年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

  • 市場促進要因
  • 市場の課題

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

  • 臨床試験
  • 規制当局の承認

第18章 特許情勢

第19章 ケーススタディ

第20章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Abbott Laboratories
    • bioMerieux SA
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd
    • AB Sciex Pte. Ltd.
    • DiaSorin S.p.A.
    • Quest Diagnostics Incorporated
    • Danaher Corporation

第21章 戦略的推奨

第22章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 3. Global Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 4. Global Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 5. Global Endocrine Testing Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 7. North America Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 8. North America Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 9. North America Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 10. North America Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. United States Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 13. United States Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 14. United States Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 15. Canada Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Canada Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 17. Canada Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 18. Canada Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 19. Mexico Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. Mexico Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 21. Mexico Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 22. Mexico Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 23. Europe Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Europe Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 25. Europe Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 26. Europe Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 27. Europe Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Germany Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 30. Germany Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 31. Germany Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 32. France Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 33. France Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 34. France Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 35. France Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 36. Italy Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 37. Italy Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 38. Italy Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 39. Italy Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 40. United Kingdom Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. United Kingdom Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 42. United Kingdom Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 43. United Kingdom Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 44. Russia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Russia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 46. Russia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 47. Russia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 48. Netherlands Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Netherlands Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 50. Netherlands Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 51. Netherlands Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 52. Spain Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Spain Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 54. Spain Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 55. Spain Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 56. Turkey Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Turkey Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 58. Turkey Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 59. Turkey Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 60. Poland Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Poland Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 62. Poland Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 63. Poland Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 64. South America Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. South America Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 66. South America Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 67. South America Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 68. South America Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Brazil Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 71. Brazil Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 72. Brazil Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 73. Argentina Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 74. Argentina Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 75. Argentina Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 76. Argentina Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 77. Asia-Pacific Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 78. Asia-Pacific Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 79. Asia-Pacific Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 80. Asia-Pacific Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 81. Asia-Pacific Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 82. India Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. India Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 84. India Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 85. India Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 86. China Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 87. China Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 88. China Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 89. China Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 90. Japan Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Japan Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 92. Japan Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 93. Japan Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 94. Australia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Australia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 96. Australia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 97. Australia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 98. Vietnam Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 99. Vietnam Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 100. Vietnam Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 101. Vietnam Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 102. South Korea Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. South Korea Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 104. South Korea Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 105. South Korea Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 106. Indonesia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. Indonesia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 108. Indonesia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 109. Indonesia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 110. Philippines Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 111. Philippines Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 112. Philippines Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 113. Philippines Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 114. Middle East & Africa Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 115. Middle East & Africa Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 116. Middle East & Africa Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 117. Middle East & Africa Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 118. Middle East & Africa Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 120. Saudi Arabia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 121. Saudi Arabia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 122. Saudi Arabia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 123. UAE Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 124. UAE Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 125. UAE Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 126. UAE Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 127. South Africa Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 128. South Africa Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 129. South Africa Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 130. South Africa Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 131. By Test Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 132. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX12292

Global endocrine testing market is projected to witness a CAGR of 8.17% during the forecast period 2024-2031, growing from USD 13.03 billion in 2023 to USD 24.42 billion in 2031. The market's growth is supported by the rising incidences of endocrine disorders, increasing awareness about preventive healthcare, and growing product launches by market players with enhanced features and patient convenience. In August 2023, the US Food and Drug Administration (FDA) listed the Mira Fertility Ovum Wand as an over-the-counter tool for tracking follicle-stimulating hormone (FSH) levels in urine. The wand can provide lab-accurate FSH levels for assessing fertility, predicting menopause, and supporting ovulation predictions.

Endocrine testing is essential for identifying abnormalities and imbalances in the endocrine system and assessing hormone levels for management and early detection of health conditions such as reproductive issues, diabetes, and thyroid disorders. Increasing investments by the healthcare sector to bolster the accessibility and affordability of these tests are expected to influence the market's expansion positively.

Furthermore, the rising awareness among the general population about endocrine disorders and the increasing efforts by various healthcare organizations to boost the accessibility of endocrine testing are providing lucrative growth opportunities to the market. Several healthcare organizations and government institutions are increasingly focusing on regular checkups for population groups that are at a higher risk of developing diabetes and thyroid disorders. Meanwhile, the general population is seeking regular health checkups to identify potential health issues on time due to increasing health consciousness. Additionally, the shift towards preventive healthcare is also propelling the demand for endocrine testing in various regions across the globe.

Increasing Prevalence of Endocrine Disorders Boosts Market Demand

Factors such as environmental influence, lifestyle changes, and genetic predisposition contribute significantly to endocrine disorders. These disorders also occur if the body cannot respond to hormones as it is supposed to. According to a National Center for Biotechnology Information (NCBI) study, the prevalence of endocrine disorders in adults in the United States is at least 5%. The rising cases of endocrine disorders are thus bolstering the reliance on endocrine testing to detect hormonal abnormalities and identify diseases.

The increasing incidences of hypothyroidism and diabetes, coupled with the increasing awareness about such conditions, is another major factor boosting the global endocrine testing market size.

Additionally, environmental factors and evolving lifestyles are also propelling the prevalence of endocrine disorders. Rising exposure to endocrine-disrupting chemicals, poor diet, stress, and sedentary habits have also been linked with the growing incidences of endocrine diseases. Endocrine-disrupting chemicals are usually found in a wide range of products, from pesticides to plastics, and have been shown to interfere with optimal hormone functioning, resulting in conditions such as reproductive health issues and thyroid imbalance.

Development of Novel Technologies Supports Market Expansion

The development of novel products and technologies plays a vital role in expanding the global endocrine testing market. Advancements in monitoring and diagnostics allow the development of endocrine testing solutions that deliver more reliable and faster results, allowing healthcare professionals to diagnose complex hormonal issues effectively. The growing demand for efficient, accessible, and patient-friendly testing solutions is thus propelling the growth of the endocrine testing market. Healthcare companies and startups across the globe are actively working on launching newer endocrine testing devices.

In July 2023, Mylab Discovery Solutions Pvt. Ltd., a Pune-based biotech startup, launched the Mybox+ diagnostic device with a broad range of tests, including biomarker (CRP, D-Dimer), cardiac marker (Troponin), and thyroid panel (T-3, T-4, TSH). Introducing this solution and the Dry Luminescence technology shows a transformative step in diagnostics and empowers clinics and labs by allowing them to provide a wide range of tests, thus aiding them in improving patient care. This technology offers a game-changing solution for clinics and small laboratories that have previously faced limitations in performing various tests and had to rely on larger facilities, often resulting in increased costs and delayed results. Thus, developing novel technologies improves patient convenience and positively influences the expansion of the endocrine testing market.

Thyroid Stimulating Hormone (TSH) Test Accounts for Significant Market Share

The growth of the segment is supported by increasing awareness about the importance of early detection of thyroid disorders and the rising prevalence of such conditions. According to the estimates of the American Thyroid Association, approximately 20 million Americans have some type of thyroid disease. Thyroid testing focuses on checking T3, T4, and TSH levels. It is one of the most performed endocrine tests across the globe as the incidences of hyperthyroidism and hypothyroidism increase. The growing efforts by the leading market players to ensure the availability of accurate and user-friendly testing devices and home-use testing kits are also expected to bolster the segment's expansion and provide lucrative growth opportunities to the global endocrine testing market.

Additionally, the increasing integration of TSH tests in preventive healthcare practices, particularly in population groups that are at high risk or have a history of thyroid disorders, is also propelling the segment's growth. Early detection can aid healthcare providers in preventing the occurrence of serious complications, including fertility issues, metabolic problems, and cardiovascular diseases. Furthermore, a rising number of healthcare professionals are advocating regular TSH testing for patients showing non-specific symptoms such as weight changes, fatigue, and depression, further bolstering the test's demand.

North America Holds Major Market Share

The rapid expansion of the market in the region can be attributed to the expansion of the population, growth of the healthcare sector, introduction of proactive government measures and policies, increasing the burden of different diseases, and rising awareness among the patient population. The strong presence of leading market players and the easy availability of healthcare services are also positively influencing the market's expansion.

The rising cases of endocrine-related diseases such as thyroid cancer are also bolstering the market demand in North America. According to the estimates of the American Cancer Society, approximately 44,020 new cases of thyroid cancer are expected to be reported in the United States in 2024. Additionally, the presence of various organizations that monitor and screen thyroid dysfunction and are devoted to thyroid biology and prevention and treatment of various thyroid diseases also provides lucrative growth opportunities to the market.

Furthermore, the rising cases of diabetes and the increasing requirement for insulin testing are also expected to bolster the market's demand. As per the estimates of the Centers for Disease Control and Prevention, approximately 38 million individuals in the United States have diabetes.

Future Market Scenario (2024-2031F)

As per the global endocrine testing market analysis, the demand is expected to be driven by increasing emphasis on preventive healthcare, rapid advancements in diagnostic technologies, and increasing incidences of endocrine disorders. Additionally, the rising requirement for point-of-care testing and increasing integration of machine learning and artificial intelligence in diagnostics is expected to drive innovation and propel the global endocrine testing market growth. The increasing prevalence of various endocrine disorders, including thyroid disorders and diabetes, in combination with supportive reimbursement policies, is expected to drive the global endocrine testing market demand. As per the estimates by the International Diabetes Federation (IDF), approximately 783 million individuals across the globe will be living with diabetes by 2045.

Additionally, the rapid expansion of the population and increasing burden on the healthcare sector are also expected to provide lucrative growth opportunities for the market. Endocrine testing is usually deployed in cases where doctors suspect that the patient might have an endocrine disorder or receive abnormal results for other function studies. The blood tests aid in confirming or eliminating suspicions and allow the identification of the root cause of the problem.

Key Players Landscape and Outlook

Various healthcare companies across the globe are actively working on delivering testing solutions that provide rapid and precise results. These companies are also actively working to raise funding to advance endocrine testing technologies. In April 2023, Eli Health raised USD 3.6 million to advance women's health with the help of saliva-based hormone monitoring technology. Hormone fluctuations affect a wide range of conditions, and women experience symptoms through puberty and post-menopause. Despite the accessibility of at-home hormone urine tests, the only options available outside of fertility are not appropriate for long-term and high-frequency testing due to high waiting time and costs. Thus, Eli Health is working on providing real-time insights into hormone levels with the help of saliva testing that can be tracked over time, unlike the traditional tests or methods that can only provide an isolated snapshot of hormone levels.

Similarly, in May 2022, a Berlin-based startup raised approximately USD 10.13 million (€9.3 million) in funding to expand their hormone tracking technology. Their biosensor mini lab allows women to discover their progesterone levels regularly by performing a saliva test. Such funding is expected to aid healthcare companies in bridging the gaps in women's health.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Endocrine Testing Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Test Type
      • 4.2.1.1. Thyroid Stimulating Hormone (TSH) Test
      • 4.2.1.2. Insulin Test
      • 4.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
      • 4.2.1.4. Prolactin Test
      • 4.2.1.5. Luteinizing Hormone (LH) Test
      • 4.2.1.6. Progesterone Test
      • 4.2.1.7. Others
    • 4.2.2. By Technology
      • 4.2.2.1. Tandem Mass Spectrometry
      • 4.2.2.2. Immunoassay
      • 4.2.2.3. Monoclonal and Polyclonal Antibody Technologies
      • 4.2.2.4. Sensor Technology
      • 4.2.2.5. Clinical Chemistry
      • 4.2.2.6. Others
    • 4.2.3. By End-user
      • 4.2.3.1. Hospitals
      • 4.2.3.2. Clinical Laboratories
      • 4.2.3.3. Diagnostic Centers
      • 4.2.3.4. Ambulatory Care Centers
      • 4.2.3.5. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Test Type
    • 4.3.2. By Technology
    • 4.3.3. By End-user
    • 4.3.4. By Region

5. North America Endocrine Testing Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Test Type
      • 5.2.1.1. Thyroid Stimulating Hormone (TSH) Test
      • 5.2.1.2. Insulin Test
      • 5.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
      • 5.2.1.4. Prolactin Test
      • 5.2.1.5. Luteinizing Hormone (LH) Test
      • 5.2.1.6. Progesterone Test
      • 5.2.1.7. Other
    • 5.2.2. By Technology
      • 5.2.2.1. Tandem Mass Spectrometry
      • 5.2.2.2. Immunoassay
      • 5.2.2.3. Monoclonal and Polyclonal Antibody Technologies
      • 5.2.2.4. Sensor Technology
      • 5.2.2.5. Clinical Chemistry
      • 5.2.2.6. Others
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals
      • 5.2.3.2. Clinical Laboratories
      • 5.2.3.3. Diagnostic Centers
      • 5.2.3.4. Ambulatory Care Centers
      • 5.2.3.5. Others
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Endocrine Testing Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Test Type
          • 5.3.1.2.1.1. Thyroid Stimulating Hormone (TSH) Test
          • 5.3.1.2.1.2. Insulin Test
          • 5.3.1.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
          • 5.3.1.2.1.4. Prolactin Test
          • 5.3.1.2.1.5. Luteinizing Hormone (LH) Test
          • 5.3.1.2.1.6. Progesterone Test
          • 5.3.1.2.1.7. Others
        • 5.3.1.2.2. By Technology
          • 5.3.1.2.2.1. Tandem Mass Spectrometry
          • 5.3.1.2.2.2. Immunoassay
          • 5.3.1.2.2.3. Monoclonal and Polyclonal Antibody Technologies
          • 5.3.1.2.2.4. Sensor Technology
          • 5.3.1.2.2.5. Clinical Chemistry
          • 5.3.1.2.2.6. Others
        • 5.3.1.2.3. By End-user
          • 5.3.1.2.3.1. Hospitals
          • 5.3.1.2.3.2. Clinical Laboratories
          • 5.3.1.2.3.3. Diagnostic Centers
          • 5.3.1.2.3.4. Ambulatory Care Centers
          • 5.3.1.2.3.5. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Endocrine Testing Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Endocrine Testing Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Endocrine Testing Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Endocrine Testing Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Abbott Laboratories
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. bioMerieux SA
    • 20.3.3. Siemens Healthineers AG
    • 20.3.4. Thermo Fisher Scientific Inc.
    • 20.3.5. Agilent Technologies, Inc.
    • 20.3.6. F. Hoffmann-La Roche Ltd
    • 20.3.7. AB Sciex Pte. Ltd.
    • 20.3.8. DiaSorin S.p.A.
    • 20.3.9. Quest Diagnostics Incorporated
    • 20.3.10. Danaher Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer